Abstract: Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory compound of low water solubility in a therapeutically effective amount, wherein the compound is present in the form of solid particles, about 25% to 100% by weight of which are smaller than 1 micrometer. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders and have particular advantages where rapid onset of therapeutic effect is desired. The novel Form I and Form II crystalline forms of celecoxib are described. The crystalline forms have unique chemical and physical properties relative to other solid state forms of celecoxib and are characterized by their powder x-ray diffraction (PXRD) patterns, differential scanning calorimetric (DSC) thermograms, and other physical characterizations.
Abstract: The present invention is directed to a class of 4-cyano-phenoxy derivatives of formula I and to their use as androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease excess sebum secretions and to stimulate hair growth.
Type:
Grant
Filed:
April 15, 2005
Date of Patent:
January 6, 2009
Assignee:
Pfizer Inc.
Inventors:
Lain-Yen Hu, Huangshu Lei, Daniel Y. Du, Bruce A. Lefker
Abstract: The present invention is directed generally to recombinant methods for making a desired pegylated protein and pooling of same. The method(s) yield a polypeptide product containing reduced levels of aggregate thereof pooled to provide the desired pegylated isoforms thereof.
Type:
Grant
Filed:
September 22, 2003
Date of Patent:
December 30, 2008
Assignee:
Pfizer Inc.
Inventors:
Denis M. Boyle, John J. Buckley, Gary V. Johnson, David E. Steinmeyer, Michele Toal, Serdar Aykent, Anurag S. Rathore
Abstract: This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R1—R7, X1, m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.
Type:
Grant
Filed:
February 3, 2005
Date of Patent:
December 23, 2008
Assignee:
Pfizer Inc.
Inventors:
Peter Bertinato, Michel A. Couturier, Ernest S. Hamanaka, Marcus D. Ewing, Ralph P. Robinson, Derek L. Tickner
Abstract: The invention provides compounds of formula (I), or a pharmaceutically acceptable salt of said compound, or a solvate of said compound or salt, wherein R1, R2, R3, HET, n, Q, X, Y, and Z are as described herein; compositions thereof; and uses thereof including treating Type 2 diabetes.
Abstract: Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein R represents H, C1-6 alkyl, SO2R1, SO2NR1R2, or COR1; R1 and R2 independently represent C1-6 alkyl; and Ring A represents a phenyl ring or a pyridinyl ring; may be useful in the treatment of anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea (primary and secondary), endometriosis, emesis (including motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittlesmerchz, preclampsia, premature ejaculation, premature (preterm) labor and Raynaud's disease.
Abstract: Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein: Het represents 2-pyridinyl or 2-pyrimidinyl; R1 represents H, C1-3 alkyl or a nitrogen-containing heterocyclic ring having 5 or 6 ring atoms; R2 represents H, benzyl or C1-3 alkyl; and R3 represents H, methyl, methoxy or chloro; are useful for treating anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea (primary and secondary), endometriosis, emesis (motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittlesmerchz, preclampsia, premature ejaculation, premature (preterm) labor and Raynaud's disease.
Type:
Grant
Filed:
January 11, 2005
Date of Patent:
November 11, 2008
Assignee:
Pfizer, Inc.
Inventors:
Justin S. Bryans, Patrick S. Johnson, Thomas Ryckmans, Alan Stobie
Abstract: Novel compounds and pharmaceutical compositions useful as hypocholesterolemic and hypolipidemic agents are described. More specifically, potent inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (“HMG CoA reductase”) are described. Methods of using such compounds and compositions to treat subjects, including humans, suffering from hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, Alzheimer's Disease, benign prostatic hypertrophy (BPH), diabetes and osteoporosis are also described.
Abstract: A compound of formula (I), or a pharmaceutically acceptable derivative, wherein A, B, V, W, X, Y, and Z are as defined herein; pharmaceutical compositions thereof; and uses thereof.
Type:
Grant
Filed:
May 1, 2006
Date of Patent:
October 28, 2008
Assignee:
Pfizer Inc.
Inventors:
Justin Stephen Bryans, Patrick Stephen Johnson, Thomas Ryckmans, Alan Stobie
Abstract: This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.
Type:
Grant
Filed:
September 25, 2002
Date of Patent:
October 28, 2008
Assignee:
Pfizer Inc.
Inventors:
Kimberly O. Cameron, Bruce A. Lefker, Robert L. Rosati
Abstract: The compound 2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-(trifluoromethyl) phenol may be used to prepare the compound (3R)-3-[2-hydroxy-5-(trifluoromethyl)phenyl]-N,N-diisopropyl-N-methyl-3-phenylpropan-1-aminium bromide by reaction with methyl bromide.
Type:
Grant
Filed:
March 8, 2005
Date of Patent:
October 21, 2008
Assignee:
Pfizer Inc
Inventors:
Ivan Richards, Sue K. Cammarata, Craig D. Wegner, Michael Hawley, Mark Peter Warchol, Mark Kontny, Walter Morozowich, Karen Patrice Kolbasa, Malcolm Wilson Moon, Dominique Bonafoux, Sergey Gregory Wolfson, Patrick James Lennon
Abstract: The invention provides methods and formulations for treating and preventing acute coronary syndromes. The methods of the instant invention provide safe and effective doses of an Apolipoprotein A-I Milano:phospholipid complex to reduce and stabilize atherosclerotic plaque. Pharmaceutical formulations of the Apo A-I Milano:phospholipid complexes are also provided.
Type:
Grant
Filed:
October 15, 2004
Date of Patent:
October 14, 2008
Assignee:
Pfizer Inc.
Inventors:
Charles L. Bisgaier, Narendra D. Lalwani, Wendi V. Rodrigueza, Daniel Hartman, Jan Johansson
Abstract: Use of an alpha-2-delta ligand, or a pharmaceutically acceptable derivative thereof, for the manufacture of a medicament for the treatment of premature ejaculation.
Type:
Grant
Filed:
December 2, 2003
Date of Patent:
October 7, 2008
Assignee:
Pfizer Inc.
Inventors:
Charles Price Taylor, Jr., Andrew John Thorpe, Pieter Hadewijn Van Der Graaf, Christopher Peter Wayman, David Juergen Wustrow
Abstract: The invention relates to compounds of formula (I) wherein R1, R2 and m are as defined in the description, their use as medicament, pharmaceutical compositions containing them and a process for their preparation.
Type:
Grant
Filed:
September 17, 2003
Date of Patent:
September 30, 2008
Assignee:
Warner-Lambert Company
Inventors:
Patrick Bernardelli, Fabrice Vergne, Chrystelle Mendes, Pierre G. Ducrot
Abstract: Compounds of formula (I), or a pharmaceutically acceptable derivative thereof, wherein R1 and R3 independently represent H, C1-6alkyl, C3-8cycloalkyl, or halogen; R2 represents C1-6alkyl, CF3 or aryl; a represents 1 or 2; R4, R5, R7 and R8 independently represent H, C1-6alkyl, C1-6alkyloxy, CN or halogen, or R4 and R5, or R7 and R8, together with the ring to which they are attached form an aryl or heterocyclic fused ring system; X represents C or N; Y represents CH2 or O; R6 represents H, CN or halo provided that, when X represents N, R6 is absent. The compounds are useful for treating endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), or chronic pelvic pain syndrome.
Type:
Grant
Filed:
October 11, 2007
Date of Patent:
September 16, 2008
Assignee:
Pfizer Inc
Inventors:
Paul Anthony Bradley, Kevin Neil Dack, Patrick Stephen Johnson, Sarah Elizabeth Skerratt
Abstract: The instant invention relates to a combination of an alpha-2-delta ligand and a PDEV inhibitor for use in therapy, particularly in the treatment of pain, particularly neuropathic pain. Particularly preferred alpha-2-delta ligands are gabapentin and pregabalin. A particularly preferred PDEV inhibitors is sildenafil.
Type:
Grant
Filed:
February 3, 2004
Date of Patent:
September 2, 2008
Assignee:
Pfizer Inc.
Inventors:
Mark John Field, Richard Griffith Williams
Abstract: The present invention involves intermediates, including a 7?-substituted steroid (II), and processes which are used to prepare eplerenone, a useful pharmaceutical agent.
Abstract: The present invention involves intermediates, including a 7?-substituted steroid (II), and processes which are used to prepare eplerenone, a useful pharmaceutical agent.
Abstract: The present invention involves intermediates, including a 7?-substituted steroid (II), and processes which are used to prepare eplerenone, a useful pharmaceutical agent.